3-methylpyrrolo[1,2-a]pyrazine | 64608-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡嗪类
• 英文名称: 3-methylpyrrolo[1,2-a]pyrazine
• CAS: 64608-61-3
• 化学式: C₈H₈N₂
• 分子量: 132.165
• InChiKey: XYRFUMWGAXDPKS-UHFFFAOYSA-N

物化性质

• 熔点：
  76-81 °C
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-methylpyrrolo[1,2-a]pyrazine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 1.25h， 以76%的产率得到6-bromo-3-methylpyrrolo[1,2-a]pyrazine
  参考文献：
  名称：

  2-甲酰基-1-炔丙基吡咯级联合成中氮茚和吡咯并[1,2-a]吡嗪

  摘要：

  通过取代的 2-甲酰基-N-炔丙基吡咯与活性亚甲基化合物（如硝基甲烷、丙二酸烷基酯、氰基乙酸甲酯和丙二腈）的级联缩合/环化/芳构化反应，直接合成中氮茚和吡咯并[1,2- a ]吡嗪. 在碱性条件下，反应顺利进行，得到相应的6,7-二取代中氮茚。吡咯类似物与乙酸铵的缩合产生高产率的吡咯并[1,2- a ]吡嗪。N -Allenyl-2-formylpyrroles 作为比 2-formyl-N 更具反应性的底物-炔丙基吡咯，以更高的产量提供预期的中氮茚。因此，在环化反应之前，在一些N-炔丙基吡咯的反应机理中，可能生成了一种含有丙二烯基的中间体作为反应性物质。

  DOI：

  10.1039/d1ob01839f
• 作为产物：
  描述：

  1-(2-oxopropyl)-1H-pyrrole-2-carbaldehyde 在 ammonium acetate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以81%的产率得到3-methylpyrrolo[1,2-a]pyrazine
  参考文献：
  名称：

  Diversity-oriented decoration of pyrrolo[1,2-a]pyrazines

  摘要：

  Diversity-oriented synthesis of a chemical library based on a pyrrolo[1,2-a]pyrazine core is described by using palladium-catalyzed direct C6 arylation of pyrrolo[1,2-a]pyrazines with various aryl bromides. The starting materials, pyrrolo[1,2-a]pyrazines, were easily synthesized by the base-mediated N-alkylation of pyrrole-2-carboxaldehyde with several 2-bromoacetophenones followed by dehydrative cyclization with incorporation of nitrogen by the action of ammonium acetate. Introduction of other functional groups on this chemical scaffold is also discussed herein. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.08.003

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• [EN] NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] NOUVEAUX DÉRIVÉS D'OXIMES ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2011051478A1

  公开（公告）日：2011-05-05

  The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGiuR4.

  本发明提供了一般式（I）的新羟肟衍生物，包含它们的药物组合物以及它们用于治疗和/或预防与改变的谷氨酸信号和/或功能有关的疾病，和/或在哺乳动物中改变谷氨酸水平或信号会影响的疾病。本发明进一步提供了一般式（I）的新羟肟衍生物，它们是对谷氨酸敏感的神经系统受体的调节剂，因此特别适用于治疗和/或预防急性和慢性神经和/或精神障碍。在特定实施例中，本发明的新羟肟衍生物是代谢型谷氨酸受体（mGluRs）的调节剂。本发明还提供了mGluRs的正向变构调节剂，更具体地说是mGluR4的正向变构调节剂。
• Electrophilic acetylation and formylation of pyrrolo[1,2-a]pyrazines: substituent effects on regioselectivity
  作者：Dileep Kumar Singh、Ikyon Kim

  DOI：10.24820/ark.5550190.p010.807

  日期：——

  Described herein is electrophilic acetylation and formylation of pyrrolo[1,2-a]pyrazines with substituent(s) at C1 and/or C3 position(s) where substituents around the core skeleton allowed regiodivergent access to C6or C8-acetylpyrrolo[1,2-a]pyrazines. While acetylation of pyrrolo[1,2-a]pyrazines (R(1) = H and R(3) = aryl or methyl) mainly gave rise to C8-acetylated products, acetylation with pyrrolo[1

  本文描述了在 C1 和/或 C3 位置具有取代基的吡咯并 [1,2-a] 吡嗪的亲电乙酰化和甲酰化，其中核心骨架周围的取代基允许区域发散地进入 C6 或 C8-乙酰基吡咯并 [1,2 -a]吡嗪。吡咯并[1,2-a]吡嗪（R(1) = H和R(3) =芳基或甲基）的乙酰化主要产生C8-乙酰化产物，吡咯并[1,2-a]吡嗪乙酰化（ R(1) = 甲基和 R(2) = 芳基或甲基）提供 C6-乙酰化化合物作为主要产物。相比之下，吡咯并 [1,2-a] 吡嗪的 Vilsmeier-Haack 甲酰化发生在 C6 位置，而与 C1 和/或 C3 位点的取代基无关。
• QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
  申请人：Abbvie Deutschland GmbH & Co. KG

  公开号：US20170260158A1

  公开（公告）日：2017-09-14

  The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT 6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT 6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT 6 receptor.

  本发明涉及公式I的喹啉化合物，其中变量的定义如索引和描述中所述。本发明还涉及含有这种化合物的药物组合物，以及它们作为5-HT6受体调节剂的用途，用于制备用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的药物，以及用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的方法。
• 피롤로[1,2-a]피라진 유도체, 이의 약학적으로 허용가능한 염, 이들 화합물의 제조방법 및 이를 유효성분으로 함유하는 골다공증 치료 또는 예방용 약학조성물
  申请人：UIF (University Industry Foundation), Yonsei University 연세대학교 산학협력단(220050095099) BRN ▼110-82-10500

  公开号：KR101756934B1

  公开（公告）日：2017-07-12

  본 발명은 피롤로[1,2-a]피라진 유도체 및 이의 약학적으로 허용가능한 염에 관한 것으로, 본 발명에 따른 피롤로[1,2-a]피라진 유도체 및 이의 약학적으로 허용가능한 염은 파골세포의 형성을 억제하는데 작용하여 파골세포의 작용에 의해 발생될 수 있는 골다공증 질환의 예방 또는 치료제로 유용하게 적용할 수 있다.

  本发明涉及吡咯[1,2-a]吡嗪衍生物及其药学上可接受的盐，根据本发明的吡咯[1,2-a]吡嗪衍生物及其药学上可接受的盐，可有效抑制成骨细胞的形成，从而可用于预防或治疗由成骨细胞活动引起的骨质疏松症。